Abstract Details

Title Anti-CGRP Monoclonal Antibodies for Neuropathic Pain in Patients with Migraine Headache

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) Neuromuscular and Clinical Neurophysiology (EMG) Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 072

Objective The aim of this study was to assess the effectiveness of anti-CGRP monoclonal antibodies for neuropathic pain in patients with coexisting chronic migraine.

Background Besides its contribution to pain transmission in migraines, there is some evidence that calcitonin gene-related peptide (CGRP) may also play a role in peripheral neuropathy and neuropathic pain, though this has not been explored.

Design/Methods A retrospective chart review was conducted of 14 patients who were administered anti-CGRP monoclonal antibodies with a diagnosis of both chronic migraine and peripheral neuropathy with neuropathic pain. We collected data on demographics, clinical features, medications taken for neuropathy, and patient-reported scores on the neuropathy pain scale (NPS) and frequency of migraine headache days (MHDs) per month. NPS scores ranged 0-100. Data were collected 3 months before treatment, at baseline, and 3, 6, 9, and 12 months after treatment.

Results The patients included in this study were an average age of 48.5 years (range 38-60). Diabetes was the cause of neuropathy in 6 patients (43%), trisulfated heparin disaccharide (TS-HDS) was the cause in 2 patients (14%), alcohol was the cause in 1 patient (7%), and the cause of neuropathy was idiopathic in 5 patients (36%). Patients observed a 41.7% decrease in NPS scores from 89.3 at baseline to 52.1 at 12 months post-treatment (p<0.05). Additionally, there was a 33.3% decrease in MHDs per month from 19.8 at baseline to 13.2 at 12 months post-treatment (p<0.05).

Conclusions The administration of anti-CGRP monoclonal antibodies improved neuropathic pain in patients who also had chronic migraine.

Authors/Disclosures
Seung Ah Kang PRESENTER	Seung Ah Kang has nothing to disclose.
Raghav Govindarajan, MD, FAAN (HSHS St. Elizabeth Medical Group)	Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MT pharma. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Catalyst. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche . Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amicus. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Govindarajan has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for MT pharma . Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Catalyst. Dr. Govindarajan has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Argenx. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biohaven. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Takeda. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Abbvie. The institution of Dr. Govindarajan has received research support from Band of Hope . The institution of Dr. Govindarajan has received research support from Alexion. Dr. Govindarajan has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��